ArticleAnnals of clinical microbiology and antimicrobials2026
Temporal dynamics of serum Mycoplasma pneumoniae antibodies in patients with acute respiratory infections: a large retrospective study.
Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurological Manifestations ofOpen forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveMycoplasma pneumoniae (MP) has re-emerged with a surging incidence in China following the lifting of COVID-19 non-pharmaceutical interventions, posing a critical challenge for clinical diagnosis and management of acute respiratory infections (ARI). We aimed to investigate the epidemiological characteristics of MP infection among all-age patients with ARI in China, as well as the temporal dynamics of serum MP-specific antibodies.
methodsThis retrospective study was based on the data of patients detected by total MP antibodies (predominantly IgM) in Chinese PLA General Hospital, Beijing, China between December 2022 and January 2024. Blood samples were collected from patients who visited or were hospitalized due to ARI for the detection of MP antibody. Adjusted odds ratio (aOR) and its 95% confidence interval (CI) were calculated to evaluate the association between MP antibody and outcome using logistic regression models adjusted by age groups, sex and diagnosis.
resultsTotally 18,054 patients were included in this study with the MP antibody detection rate of 36.2% (95% CI 35.5%-36.9%). The detection rate of MP antibody was higher in female than that in male (40.5% vs. 32.4%, aOR = 1.493, 95% CI 1.402-1.590, P < 0.001) and it was lower in adults compared to children (26.8% vs. 46.7%, aOR = 0.403, 95% CI 0.378-0.429, P < 0.001). The detection rate of MP antibody was the highest in the group of 10 ~ 20 years (53.7%, 95% CI 52.0%-55.4%). In all patients, the detection rate of MP antibody peaked at the 3rd week with 94.4% (95% CI 91.9%-95.0%), and then went down gradually, falling to 89.5% (95% CI 83.8%-95.1%) at the 8th week. The MP antibody peaked at the 1st week after symptom onset, followed by a gradual decline, and was predicted to turn to negative at about the 29th week. In children aged < 18 years, the interval between symptom onset and the MP antibody turning negative was about 24 weeks while it was 59 weeks in adults aged 18 ~ 59 years and 18 weeks in those aged ≥ 60 years.
conclusionsThe detection rate of MP antibody differed in the patients with different characteristics. MP antibody could persist for 29 weeks and age was a significant factor affecting the duration of MP antibody. The lack of population representativeness and other relevant variables may have some impact on the results, but these findings still provided new evidence for the understanding of the epidemiology and immunology MP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.